Nob Hill Therapeutics news
Albuquerque. NM, Nob Hill Therapeutics announced today the appointment of Craig Davies-Cutting, PhD, as Vice President of Research and Development. Dr. Davies-Cutting will contribute his extensive respiratory product development and industry expertise to the development and commercialization of Nob Hill Therapeutics’ first-of-its-kind DryNeb dry powder nebulizer inhalation drug delivery platform.
“We are thrilled to have Craig on the Nob
ALBUQUERQUE, N.M. (PRWEB) August 23, 2022
Nob Hill Therapeutics (NHT), a VIC Technology Venture Development portfolio company, announced today that it has received an HHS phase II grant (up to $1.73M) to develop an inhaled therapy to treat lung fungal infection using an innovative first-of-its-kind dry powder nebulizer delivery platform technology. The funds will be used to develop the drug powder formulation and the delivery device (DryNeb
May 1, 2022 – Inhalation therapies, despite their prevalence in treating pulmonary diseases and respiratory-related conditions, have numerous setbacks, such as the deposition of aerosolized particles in the upper airway.
Nob Hill Therapeutics has recruited global thought leaders to its Strategic Advisory Board.
Albuquerque, NM - Nob Hil
Nob Hill Therapeutics` Executive Chairman Paul Atkins will be presenting at the Partnership Opportunities in Drug Delivery (PODD) conference during the DryNeb – Advancing Pulmonar